Paul Allen ’s death shines light on non-Hodgkin lymphoma
The co-founder of Microsoft died Monday from complications with the disease, which is one of the most common cancers in the United States (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - October 16, 2018 Category: Consumer Health News Source Type: news
Value: A Balancing Act
There are perhaps few buzzwords bandied around in pharma circles as much in recent years as ‘value’. Companies are actively competing to stress value over volume and highlight their zealous efforts to go well ‘beyond the pill’ and deliver real value for every stakeholder in healthcare, from the patient up.A cynic might suggest that such talk is simply pharma marketing speak but, with ever-tightened purse strings, payers are demanding that pharma delivers on its promises, as they seek to understand how much bang for their buck they can expect when they purchase drugs.“We are over the tipping point,” says Zhen Su...
Source: EyeForPharma - October 16, 2018 Category: Pharmaceuticals Authors: Ross Davies Source Type: news
Value: A Balancing Act
There are perhaps few buzzwords bandied around in pharma circles as much in recent years as ‘value’. Companies are actively competing to stress value over volume and highlight their zealous efforts to go well ‘beyond the pill’ and deliver real value for every stakeholder in healthcare, from the patient up.A cynic might suggest that such talk is simply pharma marketing speak but, with ever-tightened purse strings, payers are demanding that pharma delivers on its promises, as they seek to understand how much bang for their buck they can expect when they purchase drugs.“We are over the tipping point,” says Zhen Su...
Source: EyeForPharma - October 16, 2018 Category: Pharmaceuticals Authors: Ross Davies Source Type: news
Mesothelioma Case Report Touts Success with Opdivo
Not every mesothelioma patient benefits from the immunotherapy drug Opdivo, but for the ones that do, the response can be lifesaving.
Opdivo, known generically as nivolumab, continues to produce dramatic results, inching it closer to FDA approval for mesothelioma cancer.
A recently published individual case report describes “an exceptional and sustained response.” Treatment with Opdivo allowed one patient to go from a downward spiral, with only weeks to live, back into the workforce.
“We were blown away by the patient’s response,” lead author Riley Jones, now in his fellowship at the University of Florida College...
Source: Asbestos and Mesothelioma News - July 23, 2018 Category: Environmental Health Authors: Daniel King Source Type: news
Cancer in Adolescence and Young Adulthood Linked to Endocrine Disease (CME/CE)
(MedPage Today) -- Association was strongest for leukemia, Hodgkin lymphoma, and brain cancer (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - June 29, 2018 Category: Endocrinology Source Type: news
VHIO is the first Spanish site to conduct CAR T cell trial against lymphoma in Europe
(Vall d'Hebron Institute of Oncology) Launched: First international clinical trial with CAR T cell therapy for patients with aggressive B-cell non-Hodgkin lymphoma (B-Cell NHL) in Europe.The trial has been designed to determine the efficacy and safety of JCAR017, a chimeric antigen receptor (CAR) T cell therapy, in the treatment of clinically selected adult patients with relapsed or refractory disease (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 15, 2018 Category: International Medicine & Public Health Source Type: news
Results of Novel Mesothelioma Drug Presented at ASCO Meeting
A multicenter phase II clinical trial involving the latest orally administered protein inhibitor drug has shown considerable promise in helping control malignant mesothelioma.
The effectiveness of tazemetostat was presented last week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
The trial study, which will conclude late 2018, involves 74 previously treated patients with recurring mesothelioma.
“We’ve seen benefit for some patients with this treatment and patients who have benefited over a long period of time,” medical oncologist Dr. Marianna Koczywas, City of Hope Cancer Treatment &am...
Source: Asbestos and Mesothelioma News - June 14, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news
FDA Approval of Brentuximab Vedotin With Chemo Offers New Hope for Stage III/IV Hodgkin Lymphoma
Recent FDA approval of front-line brentuximab vedotin with chemotherapy in patients with stage III/IV Hodgkin lymphoma offers the first new treatment for this disease in over 40 years. (Source: CancerNetwork)
Source: CancerNetwork - March 22, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Hematologic Malignancies Hodgkin Lymphoma News Source Type: news
For one early adopter, CAR T therapy means 18 months cancer-free and counting
For as long as he can remember, Josh Feldman has eagerly embraced the latest technology.Decades ago, his family was the first one on the block with a VCR. Years later, when television went hi-def, he acquired a big-screen TV and signed up for HD service.So after he was diagnosed with lymphoma, it was only natural that Feldman was driven to join clinical trials for a promising new treatment. He would become one of the first UCLA Health patients to receive CAR T therapy. When nothing else worked, the treatment beat back cancer and filled his life with new hope.“Years ago, while doing my own reading after my diagnosis, I le...
Source: UCLA Newsroom: Health Sciences - February 14, 2018 Category: Universities & Medical Training Source Type: news
Engineered Tumor-Specific T Cells May Help Relapsed Hodgkin Lymphoma Patients
A recent study found that Hodgkin lymphoma patients with active disease achieved clinical responses with tumor-specific T cells that were genetically modified to be rendered resistant to transforming growth factor beta, a cytokine expressed by most human cancers. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Hematologic Malignancies Hodgkin Lymphoma News Source Type: news
Engineered Tumor-Specific T-Cells May Help Relapsed Hodgkin Lymphoma Patients
A recent study found that Hodgkin lymphoma patients with active disease achieved clinical responses with tumor-specific T-cells that were genetically modified to be rendered resistant to transforming growth factor beta, a cytokine expressed by most human cancers. (Source: CancerNetwork)
Source: CancerNetwork - January 24, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Hematologic Malignancies Hodgkin Lymphoma News Source Type: news
T-cells engineered to outsmart tumors induce clinical responses in relapsed Hodgkin lymphoma
(Children's National Health System) A research team that includes Children's National Health System clinician-researchers has validated a way to outfox tumors. They engineered T-cells, essential players in the body's own immune system, to strip tumors of their self-preservation skill and were able to hold Hodgkin lymphoma at bay in patients with relapsed disease for more than four years. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 16, 2018 Category: International Medicine & Public Health Source Type: news
Wife who nursed husband through cancer developed disease
Jenny Thirlaway, 46, cared for husband Scott, 43, who had Hodgkin lymphoma. Then Jenny's ordeal began in February this year when she was diagnosed with bowel disease. (Source: the Mail online | Health)
Source: the Mail online | Health - December 18, 2017 Category: Consumer Health News Source Type: news
How Do You Perform the Adams Forward Bend Test?
Discussion
Scoliosis is a lateral and rotational curvature of the spine from a plumb line hanging from C7 to the floor.
Idiopathic scoliosis is the most common form. A review of scoliosis and its differential diagnosis can be found here.
Depending on the age, 2-4% of adolescents have a positive Adams Forward Bend Test when assessed and ~2% may have idiopathic scoliosis of > 10 degrees. Curve progression relates to the magnitude of the curve and the patient’s age. Thus increased risk of progression occurs in patients with higher curvature magnitude at diagnosis, females (earlier start of puberty and therefore pos...
Source: PediatricEducation.org - December 4, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
